Refine
Year of publication
Document Type
- Article (35801)
- Doctoral Thesis (6492)
- Monograph/Edited Volume (5554)
- Postprint (3296)
- Review (2292)
- Part of a Book (1065)
- Other (915)
- Preprint (567)
- Conference Proceeding (545)
- Part of Periodical (525)
Language
Keywords
- Germany (202)
- climate change (183)
- Deutschland (142)
- machine learning (84)
- European Union (79)
- diffusion (78)
- Sprachtherapie (77)
- morphology (74)
- Logopädie (73)
- Migration (73)
Institute
- Institut für Biochemie und Biologie (5462)
- Institut für Physik und Astronomie (5432)
- Institut für Geowissenschaften (3658)
- Institut für Chemie (3482)
- Wirtschaftswissenschaften (2645)
- Historisches Institut (2514)
- Department Psychologie (2348)
- Institut für Mathematik (2145)
- Institut für Romanistik (2108)
- Sozialwissenschaften (1883)
Solid organ transplant (SOT) recipients receive therapeutic immunosuppression that compromises their immune response to infections and vaccines. For this reason, SOT patients have a high risk of developing severe coronavirus disease 2019 (COVID-19) and an increased risk of death from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Moreover, the efficiency of immunotherapies and vaccines is reduced due to the constant immunosuppression in this patient group. Here, we propose adoptive transfer of SARS-CoV-2-specific T cells made resistant to a common immunosuppressant, tacrolimus, for optimized performance in the immunosuppressed patient. Using a ribonucleoprotein approach of CRISPR-Cas9 technology, we have generated tacrolimus-resistant SARS-CoV-2-specific T cell products from convalescent donors and demonstrate their specificity and function through characterizations at the single-cell level, including flow cytometry, single-cell RNA (scRNA) Cellular Indexing of Transcriptomes and Epitopes (CITE), and T cell receptor (TCR) sequencing analyses. Based on the promising results, we aim for clinical validation of this approach in transplant recipients. Additionally, we propose a combinatory approach with tacrolimus, to prevent an overshooting immune response manifested as bystander T cell activation in the setting of severe COVID-19 immunopathology, and tacrolimus-resistant SARS-CoV-2-specific T cell products, allowing for efficient clearance of viral infection. Our strategy has the potential to prevent severe COVID-19 courses in SOT or autoimmunity settings and to prevent immunopathology while providing viral clearance in severe non-transplant COVID-19 cases.